44 results about "Faecalibacterium prausnitzii" patented technology

The application relates to the field of biotechnology, in particular to a Faecalibacterium prausnitzii microbial anti-inflammatory molecule and a screening method and application thereof. The amino acid sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is shown in (a) or (b); (a) the amino acid sequence is shown in SEQ ID NO. 1; (b) a protein derived from (a) with anti-inflammatory activity obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence in (a). Compared with the microbial anti-inflammatory molecule protein of a representative strain A2-165 of the Faecalibacterium genus, the inhibiting effects of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule on the NF-kappa B signal pathway and the inflammatory factor TNF alpha are 50% and 56% respectively, and the anti-inflammatory effect (inhibiting the NF-kappa B signal pathway) of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule screened in the application can reach more than 90%, and the Faecalibacterium prausnitzii microbial anti-inflammatory molecule has the advantages of small use dosage and strong anti-inflammatory effect.

The invention relates to the technical field of pet feed additives, and discloses a pet coated enzyme-containing metagen feed additive and a preparation method thereof, the additive comprises a core particle formed by mixing a metagen and a slow-release coated compound enzyme, and an enteric layer coated outside the core particle. The preparation method comprises the following steps: respectively preparing the metagen and the slow-release coated compound enzyme, mixing the metagen and the slow-release coated compound enzyme to prepare core particles, and then carrying out enteric coating on the core particles. The activity of functional components is protected through a double coating structure, so that the functional components are released in an intestinal tract in a targeted manner and have a synergistic effect. The additive can effectively improve pet protein digestion, regulate intestinal microenvironment, remarkably proliferate beneficial bacteria such as lactobacillus and clostridium praeparatum and inhibit escherichia coli, so that soft stool is reduced, and intestinal health of pets is maintained.

The invention discloses a clostridium praeparatum vesicle targeting inflammatory bowel disease tissues as well as preparation and application of the clostridium praeparatum vesicle. The vesicle is secreted by clostridium praeparatum ATCC27766, and the average particle size of the vesicle is 100-250 nm. Experimental data show that the vesicles have intestinal disease site targeting, can effectively remodel the intestinal immune microenvironment of ulcerative colitis patients, and inhibit the inflammation process through chemotactic factor secretion of macrophages. The clostridium praeparatum vesicle and the preparation can effectively overcome the defect that clostridium praeparatum and butyrate secreted by the clostridium praeparatum are prone to failure, the treatment means of ulcerative colitis are enriched, and the application prospect of anaerobic probiotics is widened.

The present invention provides the use of Faecalibacterium prausnitzii DSM 17677 in the preparation of a product for preventing and treating porcine epidemic diarrhea virus infection, belonging to the field of biomedicine technology. The present invention proposes for the first time that Faecalibacterium prausnitzii DSM 17677 can inhibit the replication of the PEDV virus and reduce the viral titer, thereby effectively preventing or treating diseases caused by PEDV virus infection. The present invention proposes for the first time that Faecalibacterium prausnitzii DSM 17677 can significantly inhibit PEDV infection through competitive adhesion and exert a protective effect on viral target cells. The present invention provides a theoretical basis for the use of Faecalibacterium prausnitzii DSM 17677 as an antiviral drug and has economic value, providing a path and solution for the prevention and treatment of PEDV.

A probiotic composition for inhibiting the onset and progression of colorectal cancer, comprises one or more of a culture supernatant of Faecalibacterium prausnitzii (Fp) cells, live Fp cells, or non-viable Fp cells，wherein the probiotic composition comprises at least one metabolite of Fp, wherein the at least one metabolite is hypoxanthine. A use of the probiotic composition or hypoxanthine for manufacturing of a medicament for inhibiting the onset and progression of colorectal cancer.

The invention relates to the field of biological medicines, relates to a treatment technology for early abortion, and in particular relates to an application of Clostridium prausnitzii (Faecalibacterium prausnitzii) in preparation of a medicine for treating early abortion. An experiment of a Poly (I: C) induced early-stage abortion mouse model proves that the clostridium praeparatum can obviously reduce the embryo loss rate and improve placenta development through oral intragastric administration. The action mechanism is that maternal immune balance is regulated by increasing the proportion of regulatory T cells (Treg) and inhibiting excessive activation of an IL-17 signal channel. As human intestinal symbiotic bacteria, the clostridium praeparatum is high in safety and can be used for intervention of early abortion, especially recurrent abortion, and a new strategy is provided for clinic.

The invention discloses an anaerobic bacterium co-culture device and application thereof.The anaerobic bacterium co-culture device comprises a first screw injector 1 and a second screw injector 8, the first screw injector 1 is sequentially connected with a first Luer external thread adapter 2, a first hose 3, a filter membrane clamp 4, a second hose 5, a second Luer external thread adapter 6 and the second screw injector 8, and the first Luer external thread adapter 2, the first hose 3, the filter membrane clamp 4, the second hose 5, the second Luer external thread adapter 6 and the second screw injector 8 are sequentially connected; and a filter membrane 7 is arranged in the filter membrane clamp 4. The anaerobic bacteria co-culture device is simple in structure, low in cost and convenient to use, can easily simulate an anaerobic environment and co-culture anaerobic bacteria without anaerobic culture equipment, can well culture two different species of bacteria in the same liquid environment without cross contamination, is suitable for co-culture of various common anaerobic bacteria, and has a wide application prospect. Such as salmonella typhimurium, bifidobacterium breve, fecal bacillus przewalskii, ackermania or prevotella. The method has great benefits for the initial research of related research projects of bacterial interaction.

The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health.In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.

The present invention is directed to beneficially directing the bidirectional communication that exists between the brain and the gut so as to influence brain physiology, psychological responses and ultimately behavior in a positive manner by regulating an individual's mood, psychological symptoms, such as anxiety and depression and stress-related changes in brain function, by modifying the gut microbiome of an individual. In various embodiments, an individual's microbiome is modified in a manner to reduce the likelihood of stress, to reduce or treat symptoms affecting mental health and to promote the mental health of the individual. In certain embodiments, administration to an individual of at least three different bacteria species are combined to modify an individual's microbiome, selected from the group of Lacticaseibacillus paracasei, Coprococcus, Roseburia, Bifidobacterium, L. casei and Faecalibacterium prausnitzii, to reduce adverse psychological and / or physiological responses attendant to psychological stress.

The present invention relates to a synbiotic composition comprising probiotics and dietary fiber, wherein the probiotics are selected from Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) BPB22; dietary fiber is derived from one or more of white lentils, goji berries, red dates, bitter melon, lotus seeds, buckwheat, Chinese yam, oats, corn silk, and coix seed. The synbiotic composition of the present invention can significantly improve symptoms of a high-fat diet, including excessive caloric intake, weight gain, fat accumulation, muscle loss, impaired insulin sensitivity, impaired glucose tolerance, insulin resistance, and decreased fecal short-chain fatty acid levels.

The invention discloses a microbial marker for treating recurrent clostridium difficile infection based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Coprococcos, Eubacter coprostanoliganes, Agatrobacter rectas, Dorea foetida, Blauria obbe, Klebsiella foetida, Blauria foetida, Blauria ovaticus and Gemmigerformation. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Citrobacter coprostanoliganes, Citrobacter rectas, according to the invention, through metagenome sequencing and a machine learning algorithm, key microbial markers significantly related to recurrent clostridium difficile symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of recurrent clostridium difficile infection.

This invention discloses a dietary factor and its combination that targets gut microbiota to improve exercise performance, belonging to the fields of microbial technology and pharmaceutical technology. Experimental verification shows that the dietary factor combination can increase the abundance of *Eubacterium rectale*, *Faecalibacterium prausnitzii*, and *Veillonella* species; a combination of galactooligosaccharides, burdock seed, matsutake polysaccharide, and galactooligosaccharides; a combination of burdock seed and matsutake polysaccharide; and a combination of burdock seed and galactooligosaccharides can increase the concentration of fatty acid amides; curcumin and the combination of curcumin, burdock seed, and galactooligosaccharides show the best effect in promoting the content of fecal microbiota after acetic acid fermentation; and a mixed combination of *Bifidobacterium adolescentis* CCFM1066, *Bifidobacterium longum* CCFM1306, curcumin, inulin, burdock seed, matsutake polysaccharide, and galactooligosaccharides shows the most significant effect in increasing the time spent swimming at exhaustion under load in exercised mice.

The invention relates to heterobacterium faecalis, in particular to application of heterobacterium faecalis DSM 13633 or a culture solution thereof in preparation of a medicine for preventing or treating diabetic nephropathy. The invention proves that the urine volume of a mouse with diabetic nephropathy can be reduced by the heterobacterium faecalis DSM 13633, and the levels of urinary albumin, urine creatinine and urea nitrogen can be reduced, so that the Allobacter sterilicis can be used for improving the renal function impairment induced by hyperglycemia. Meanwhile, the pathological evaluation of kidney tissue shows that the Allobaculum stericolicis can be used for improving the renal lesion of the hyperglycemia mouse. According to the present invention, with the application of the Allobaculum stericoranis, the mRNA expression level of M1 type macrophage markers (Il6, Il1beta, iNOS) in the diabetic mouse kidney tissue can be reduced, the mRNA expression level of M2 type macrophage markers (Arg1, Il10, CD206) can be increased, and the results show that the Allobaculum stericoranis can alleviate the hyperglycemia induced renal tissue inflammation state;

The application provides application of intestinal flora as a marker in preparation of a product for evaluating treatment effect of inflammatory bowel disease. The feasibility of using a microbial spectrum to predict the curative effect of drug treatment on patients with inflammatory bowel disease is achieved, and the achievement can accurately identify patients who need to optimize the treatment scheme in the early stage of the disease, thereby significantly improving the prognosis of the patients. Meanwhile, a construction method of an intestinal flora biomarker prediction model is provided, and through the combination of Faecalibacterium prausnitzii, Blautia massiliensis and Phascolarctobacterium faecium, the precise prediction of the invalid condition of drug treatment is realized, which highlights the potential of the new tool for early identification of patients who may need to optimize the treatment.

The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.

The application discloses an adult depression intestinal microorganism marker and application thereof, and belongs to the field of biological medicine. The microorganism marker comprises one or more of the following: Clostridium aldrichii, Coprococcus comes, Klebsiella pneumoniae, Bifidobacterium adolescentis, Bacteroides vulgatus, Eubacterium eligens and Faecalibacterium prausnitzii. The application provides a product (such as a kit) comprising detection reagents for detecting the relative abundance of the microorganism marker. The product provided by the application has good feasibility and accuracy, and can effectively evaluate the risk of whether an adult has depression, thereby providing a new tool for clinical diagnosis.

The application discloses an intestinal flora marker related to obstructive sleep apnea with obesity, a product and application thereof, and the intestinal flora marker combination is a marker combination composed of Streptococcus thermophilus, Faecalibacterium prausnitzii, Dorea longicatena and Bacteroides finegoldii. The application of a reagent for detecting the intestinal flora marker combination in preparation of a product for diagnosing obstructive sleep apnea with obesity is characterized in that the reagent comprises cetyltrimethylammonium bromide. The application provides a new idea and approach for diagnosis and treatment of obstructive sleep apnea with obesity.

The invention discloses an engineered bacterial vesicle co-loaded with apatinib and a PD-L1 antibody and a preparation method and application thereof.According to the engineered bacterial vesicle, an outer membrane vesicle derived from coprobacterium rodent serves as a carrier, a chemotherapeutic drug apatinib is loaded in the engineered bacterial vesicle, the surface of the engineered bacterial vesicle is modified with the PD-L1 antibody through chemical coupling, and the engineered bacterial vesicle is named as Apatinib-MVs alpha PD-L1; the engineered bacterial vesicle can synergistically deliver apatinib and a PD-L1 antibody to a breast cancer focus, so that synergistic interaction of chemotherapy and immunotherapy is realized; in-vitro experiments show that the engineered bacterial vesicles can significantly inhibit proliferation, migration and invasion of breast cancer cells; in-vivo experiments show that the compound can effectively inhibit tumor growth and remarkably increase infiltration of CD8 + T cells in a tumor microenvironment, and a new drug delivery platform is provided for combined treatment of breast cancer.

The present invention discloses an application of tea lovage polysaccharide in the preparation of a drug for regulating intestinal flora in inflammatory bowel disease, and belongs to the technical field of polysaccharide extraction process optimization and intestinal flora regulation. Specifically, the present invention provides an economical and efficient extraction process and new use of tea lovage polysaccharide for the preparation of a preparation or composition. By increasing the relative abundance of probiotic flora, reducing the relative abundance of harmful bacteria, regulating the structure of intestinal flora, etc., the symptoms of intestinal flora disorder in inflammatory bowel disease are alleviated and treated. Tea lovage polysaccharide improves ulcerative colitis in mice by upregulating the relative abundance of probiotics such as Bacteroides and Faecalibacterium prausnitzii, and downregulating the relative abundance of pathogenic bacteria such as Proteobacteria, Gammaproteobacteria, Enterobacteriaceae and Escherichia, thereby reversing the abnormal proliferation of bacteria in mice with inflammatory bowel disease and improving the disordered intestinal flora in mice with inflammatory bowel disease.

Provided are a Faecalibacterium prausnitzii, a postbiotic thereof, and a use thereof. The Faecalibacterium prausnitzii is selected from a group consisting of an NCKUMM001 strain and an NCKUMT002 strain; the postbiotic of the Faecalibacterium prausnitzii is present in a conditioned medium thereof, and comprises an extracellular vesicle and a short-chain fatty acid. The Faecalibacterium prausnitzii and the postbiotic thereof have the effect of protecting the gut of an individual, slowing down inflammation, and regulating the expression of genes associated with lipid metabolism.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a membrane vesicle derived from coprophilobacter rodent in preparation of a medicine for preventing, treating or relieving breast cancer. The membrane vesicles derived from the coprophilobacter rodent are separated from bacterial culture supernatant of the membrane vesicles through an ultracentrifugation method; experiments show that the membrane vesicles sourced from the coprophilobacter rodent can effectively influence the biological function of a breast cancer cell line and inhibit the growth of breast cancer tumors; the research on the action mechanism of the membrane vesicles shows that the membrane vesicles derived from the coprophilobacter rodent can promote the maturation of dendritic cells in a tumor microenvironment and obviously increase the infiltration of CD8 + T cells, so that the anti-tumor immune response of a body is effectively activated; the safety evaluation shows that the membrane vesicle treatment from the coprophilobacter rodent has no toxic or side effect on the body; in conclusion, as a novel bacterium-derived immunotherapy preparation, the membrane vesicles derived from the coprobacterium rodent show a good application prospect in prevention and treatment of the breast cancer.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The present invention relates to a bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573, and / or a culture supernatant thereof, for use in the treatment and / or prevention of a Clostridium difficile infection in an individual. The present invention also relates to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, and to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

The present invention relates to a new strain of Faecalibacterium prausnitzii EB-FPDK9 and its use, which has the effects of preventing, alleviating and treating inflammatory diseases, liver diseases or metabolic diseases when a composition containing one or more selected from the following is ingested: Faecalibacterium prausnitzii EB-FPDK9, a culture solution, lysate or extract of the strain.

The present invention relates to a bacterial strain of the species Faecalibacterium prausnitzii deposited at the CNCM under accession number CNCM I-4573 and / or its culture supernatant for use in the treatment and / or prevention of Clostridioides difficile infection in an individual.

The present invention relates to systems and methods for estimating an individual's Faecalibacterium prausnitzii (Fprau) amounts and for providing personalized recommendations to maintain or improve the Fprau. In several embodiments of the invention, the individual's Fprau amounts are estimated based on their Food FrequencyQuestionnaire (FFQ) records. In several embodiments, the methods are implemented by a computer system. In several embodiments of the invention, personalized recommendations and dietary advice are given to the individual to maintain or improve said individual's Fprau.

The invention relates to the field of biological medicines, and discloses a composition and a medicine for relieving drug-induced liver injury as well as a preparation method and application of the composition and the medicine. The composition for relieving the drug-induced liver injury is prepared from clostridium praeparatum, mannan oligosaccharide, PQQ, IP6 and isogenistein. The inner layer structure of the medicine for relieving the drug-induced liver injury is used for embedding clostridium praeparatum and mannan oligosaccharide, and the outer layer structure of the medicine comprises PQQ, IP6 and isogenistein. The inner layer structure is formed by coating sodium alginate gel microspheres with chitosan; the outer layer structure is composed of hydroxypropyl methyl cellulose and sodium alginate. The survival rate of the composition for APAP-induced human hepatocyte injury reaches 85.5%, and hepatocyte injury and inflammatory response can be effectively relieved. The microcapsule structure enables the release rate of PQQ in gastric juice to be lower than 20%, the release rate of probiotics in gastric juice to be lower than 10%, and the total release rate of probiotics in intestinal segments to be higher than 90%, so that accurate delivery and stable protection of medicinal components are realized.

The invention discloses a complex microbial inoculant containing bifidobacterium and application of the complex microbial inoculant. Comprising two or more of bifidobacterium lactis BL9, bifidobacterium longum subsp. Longum KS1, clostridium pratensis GZSY3214, Leuconostoc mesenteroides PM10, and Gluconacetobacter xylinus Q1, and further comprises a preparation method of the bifidobacterium lactis BL9, a preparation method of the bifidobacterium longum subsp. Longum KS1, a preparation method of the bifidobacterium longum subsp. Longum GZSY3214, a preparation method of the bifidobacterium longum, a preparation method of the bifidobacterium longum, a preparation method of the bifidobacterium longum and a preparation method of the bifidobacterium longum, and a preparation method of the bifidobacterium longum. The complex microbial inoculant can be used for preparing milk powder, weight-losing food and fruit and vegetable beverages, and is wide in application range.

The invention discloses bacteroides simplex capable of regulating and controlling abundance of clostridium pralaense in intestinal tracts and application of the bacteroides simplex, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a strain of Bacteroides simplex CCFM1370, the Bacteroides simplex CCFM1370 is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the Bacteroides simplex CCFM1370 is GDMCC No: 64267. The bacteroides simplex CCFM1370 can effectively adjust alpha diversity and beta diversity of flora in fermentation liquor in an in-vitro simulated colon fermentation system, and the level of butyrate in the fermentation liquor and the absolute bacterial count of clostridium praeparatum are improved. And the abundance of the clostridium praeparatum can be remarkably increased by co-culturing with the clostridium praeparatum in an in-vitro YCFA culture medium. Therefore, the bacteroides simplex CCFM1370 provided by the invention has huge application prospect and commercial value in the preparation of products (such as drugs) for regulating the abundance of clostridium praeparatum so as to prevent and / or treat related diseases.